This study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. Patients with tumors for which treatment with docetaxel would be appropriate are eligible. A second part of the study will further examine the effectiveness of the combination treatment in men with prostate cancer.
No linked publications found in PubMed
Inclusion Criteria: * For Part 1: Subjects may be male or female and must be at least 18 years of age. * For Part 1: Cancer for which docetaxel treatment is appropriate. * For Part 1: Docetaxel-naïve * For Part 2: Subjects must be male and at least 18 years of age. * For Part 2: Subjects must have adenocarcinoma of the prostate confirmed by histologic/cytologic biopsy. * For Part 2: Subjects must have progressive, metastatic, AIPC and a PSA of 10 ng/ml or more after hormonal therapy prior to docetaxel treatment. Progressive disease is defined as a consistently increasing serum PSA level within 28 days prior to docetaxel administration. * Adequate organ function within 3 weeks prior to first study drug administration. * Performance status (ECOG) is less than or equal to 2. * Subject understands and agrees to procedures and participation by signing informed consent form. * Agrees to use medically accepted form of contraception. Exclusion Criteria: * Receipt of or need to continue to receive prohibited medications (listed in the protocol) more recently than the washout period (indicated in the protocol). * Surgery within 3 weeks prior to first study drug administration. * History within 5 years prior to first study drug administration of another malignancy except adequately treated Stage I/II basal/squamous cell skin cancer. * Radiation therapy to more than 25% of his/her total bone marrow during life. * Radiation therapy within 3 weeks prior to first study drug administration. * Known hypersensitivity to prednisone, docetaxel, polysorbate 80, lonafarnib, or any excipients associated with these medications. * Known contraindication to steroid use. * Known leptomeningeal or CNS metastasis. * Heart, vascular, or seizure disorder (detailed list in the protocol) within 6 months prior to first study drug administration. * Baseline QTc interval greater than 450 msec. * Grade 2 or more peripheral neuropathy or drug-related toxicity per CTCAE. Exceptions are noted in the protocol. * Any clinically significant condition or situation that the investigator thinks would interfere with the study evaluations or subject's participation. * Subject is part of staff personnel involved in the study. * Subject has known clinically significant immunosuppression.